Trials Sponsors Conditions Drugs Pricing

Conditions

Open-angle Glaucoma

Keywords

GlaucomaTravatanTrabeculectomy

Outcome Measures

Primary Outcomes (1)

Melanin Granule Count
A trabecular meshwork tissue sample was collected by the investigator. The number of pigment granules was counted for three separate microscopic fields of view. Mean melanin granule count was calculated.
Day 1

Study Arms (2)

TRAVATAN

As prescribed by physician for the treatment of open-angle glaucoma and dosed for at least two years

Procedure: Trabecular Meshwork Tissue CollectionDrug: Travoprost 0.004% ophthalmic solution

Treatment Naive

No prior exposure (or less than 1 month) to any topical, ocular prostaglandin analogue

Procedure: Trabecular Meshwork Tissue Collection

Interventions

Trabecular Meshwork Tissue CollectionProcedure

A minimum of two punches were used to remove tissue to form a sclerostomy. Tissue removed by the punch was collected for analysis. Alternatively, the tissue was collected by block excision of the meshwork with scissors at the time of sclerostomy.

TRAVATANTreatment Naive

Travoprost 0.004% ophthalmic solutionDrug

Eligibility Criteria

Age50 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

Patients were identified and enrolled from 9 study centers in the US and 1 in Spain.

You may qualify if:

Diagnosis of open-angle glaucoma without pseudoexfoliation or pigment dispersion component;

Sponsors & Collaborators

Alcon Research
Industrylead

MeSH Terms

Conditions

Glaucoma, Open-AngleGlaucoma

Interventions

TravoprostOphthalmic Solutions

Condition Hierarchy (Ancestors)

Ocular HypertensionEye Diseases

Intervention Hierarchy (Ancestors)

CloprostenolProstaglandins F, SyntheticProstaglandins, SyntheticProstaglandinsEicosanoidsFatty Acids, UnsaturatedFatty Acids

Study Officials

Theresa Landry, PhD
Alcon Research
STUDY DIRECTOR

Enrollment

88 participants (actual enrollment reported by the registry).

Study Design

Study Type: observational
Observational Model: COHORT
Time Perspective: PROSPECTIVE
Sponsor Type: INDUSTRY
Responsible Party: SPONSOR

Study Record Dates

First Submitted

December 1, 2011

First Posted

December 6, 2011

Study Start

July 2004

Date type not reported

This date has not been verified as actual or estimated.

Study Stopped

A Multicenter Study of the Pigmentation in the Trabecular Meshwork After Two Years of Treatment With TRAVATAN 0.004% Ophthalmic Solution

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Study Arms (2)

TRAVATAN

Treatment Naive

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Intervention Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Study Arms (2)

TRAVATAN

Treatment Naive

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Intervention Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record